|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
This second annual Drug Development & Delivery Respiratory eBook focuses on a few companies that are taking inhalation devices to a new level in drug delivery.
|
|
|
Karima Yadi, MSc, and Lionel Maritan, MSc, believe identifying enhanced needle solutions and offering integrated system solutions to serve the chronic disease market is a great step toward addressing improved patient outcomes and adherence.
|
|
|
Emile Youssef, MD, PhD, says due to tumor heterogeneity, the plasticity and diversity of cancer cells, and a multitude of other factors, biomarker development is a challenge, and thus explores four trends in cancer biomarker discovery.
|
|
|
Josef Bossart, PhD, explains how accurately estimating a product’s clinical development timelines is more than simply adding up the individual timelines, almost always optimistic. You need to “know” the numbers, not just calculate them.
|
|
|
Shawn Zhang, PhD, Johnathan Goldman, PhD, Xiaodong Chen, PhD, et al present a new method that not only characterizes quantitatively the microstructures of the lyophilized drug samples, but also presents the potential to correlate the microstructures with physical properties to optimize parameters in drug formulation, cycle development, process scale-up, stability control, and administration.
|
|
|
Kenji Arima, PhD, and Akihiko Watanabe, PhD, introduce NapaJen Pharma’s technology with a specific focus on solving some of the current challenges of oligonucleotide therapeutics.
|
|
|
|
|
|
|
|
|

Headquartered in Nashville,TN PMI BioPharma Solutions is a team of highly experienced life science experts providing rigorous research, pharmaceutical development, and clinical manufacturing services to clients in the pharmaceutical and biotechnology space. We pride ourselves on our abilities, integrity, and persistence in the face of challenge, and will exert maximal effort and ingenuity to achieve your goals. Click here for more.
|
|
|
|
|
|
 |
|
ImmunoMolecular Therapeutics, Inc. recently announced the dosing of the first patient in a Phase 1 study of IMT-002, an oral small molecule drug designed as a selective….
|
|
 |
|
Timber Pharmaceuticals, Inc. recently announced that all 11 sites across the US and Australia participating in the Phase 2b CONTROL study evaluating TMB-001 (topical isotretinoin) are now….
|
|
 |
|
The COVID-19 pandemic has led to temporarily increased drug sales for biggest bio/pharma companies in the first quarter (Q1) of 2020. This increase over sales forecasts….
|
|
|
|
|
Upcoming eNewsletter Features:
July 22 – Bioavailability
July 29 – Excipients
|
|
|
|
|
|
|
|